Table 1.
Eleven questions about emergency anticancer therapy in oncologic patients
| No. | Question |
|---|---|
| 1 | Is EAT in intensive care medicine feasible |
| 2 | Is EAT ever performed in your department |
| 3 | Is EAT for lymphoma under organ supporting therapy feasible |
| 4 | Is EAT for small cell lung cancer under organ supporting therapy feasible |
| 5 | Is EAT for non-small cell lung cancer with positive driver gene under organ supporting therapy feasible |
| 6 | Is Emergency radiotherapy for lung cancer under organ supporting therapy feasible |
| 7 | Is EAT for lymphoma with tumor lysis syndrome feasible |
| 8 | Is EAT for lymphoma with tumor-associated hemophagocytic lymphohistiocytosis or disseminated intravascular coagulation feasible |
| 9 | Is EAT for lymphoma with hyperleukocytosis feasible |
| 10 | Is EAT for lymphoma with plasma hyperviscosity syndrome feasible |
| 11 | Organization of multidisciplinary team of EAT |
| Intensivist and oncologist | |
| Intensivist, oncologis and pharmacist | |
| Intensivist, oncologist, pharmacist and member of the Ethics Committee | |
| Intensivist, oncologist, pharmacist, member of the Ethics Committee, and relatives |
Fig. 1.
Main findings of 10 questions about emergency anticancer therapy.
Table 2.
Attitudes towards emergency anticancer therapy between mixed and oncologic ICU physicians
| Question | Mixed ICU physicians (n =13) | Oncologic ICU (n =107) | χ2 | P value |
|---|---|---|---|---|
| Is EAT feasible | 0.578 | 0.749 | ||
| Yes | 11 (84.6) | 96 (89.7) | ||
| No | 0 (0.0) | 1 (0.9) | ||
| Not sure | 2 (15.4) | 10 (9.3) | ||
| Is EAT ever performed | 0.038 | 0.493 | ||
| Yes | 11 (84.6) | 97 (90.7) | ||
| No | 2 (15.4) | 10 (9.3) | ||
| EAT for lymphoma under organ supporting therapy | 0.387 | 0.824 | ||
| Yes | 12 (92.3) | 95 (88.8) | ||
| No | 0 (0.0) | 3 (2.8) | ||
| Not sure | 1 (7.7) | 9 (8.4) | ||
| EAT for small cell lung cancer under organ supporting therapy | 0.689 | 0.708 | ||
| Yes | 12 (92.3) | 91 (85.0) | ||
| No | 0 (0.0) | 4 (3.7) | ||
| Not sure | 1 (7.7) | 12 (11.2) | ||
| EAT for non-small cell lung cancer with positive driver gene under organ supporting therapy | 1.471 | 0.479 | ||
| Yes | 13 (100.0) | 96 (89.7) | ||
| No | 0 (0.0) | 2 (1.9) | ||
| Not sure | 0 (0.0) | 9 (8.4) | ||
| Emergency radiotherapy for lung cancer under organ supporting therapy | 1.771 | 0.412 | ||
| Yes | 10 (76.9) | 62 (57.9) | ||
| No | 1 (7.7) | 18 (16.8) | ||
| Not sure | 2 (15.4) | 27 (25.2) | ||
| EAT for lymphoma with tumor lysis syndrome | 1.925 | 0.382 | ||
| Yes | 13 (100.0) | 93 (86.9) | ||
| No | 0 (0.0) | 4 (3.7) | ||
| Not sure | 0 (0.0) | 10 (9.3) | ||
| EAT for lymphoma with tumor-associated hemophagocytic lymphohistiocytosis or disseminated intravascular coagulation | 3.122 | 0.210 | ||
| Yes | 11 (84.6) | 89 (83.2) | ||
| No | 2 (15.4) | 6 (5.6) | ||
| Not sure | 0 (0.0) | 12 (11.2) | ||
| EAT for lymphoma with hyperleukocytosis | 0.144 | 0.930 | ||
| Yes | 12 (92.3) | 99 (92.5) | ||
| No | 0 (0.0) | 1 (0.9) | ||
| Not sure | 1 (7.7) | 7 (6.5) | ||
| EAT for lymphoma with plasma hyperviscosity syndrome | 3.238 | 0.198 | ||
| Yes | 11 (84.6) | 98 (91.6) | ||
| No | 1 (7.7) | 1 (0.9) | ||
| Not sure | 1 (7.7) | 8 (7.5) | ||
| Organization of multidisciplinary team | 3.822 | 0.281 | ||
| Intensivist and oncologist | 1 (7.7) | 25 (23.4) | ||
| Intensivist, oncologis and pharmacist | 8 (61.5) | 38 (35.5) | ||
| Intensivist, oncologist, pharmacist and member of the Ethics Committee | 4 (30.8) | 42 (39.3) | ||
| Intensivist, oncologist, pharmacist, member of the Ethics Committee, and relatives | 0 (0.0) | 2 (1.9) |